SLC5A2 and vascular dementia: A population-based cohort study from the UK by Wang et al. also compared new users of SGLT2 inhibitors against DPP-4 inhibitors and found a potential, though not statistically significant, reduction in the risk of all-cause dementia (adjusted HR: 0.77; 95% CI: 0.57-1.05) and a more specific reduced risk of vascular dementia [8].